HUTCHMED (China) (HCM)
Quick facts
| Ticker | HCM (NASDAQ) |
|---|
Phase 3 pipeline
- HMPL-760 · Oncology
HMPL-760 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells. - R-GemOx · Oncology
R-GemOx is a combination of gemcitabine and oxaliplatin, used to treat various cancers.
Phase 2 pipeline
- Elunate® · Oncology
Elunate is a small molecule inhibitor of the serine protease inhibitor, serpin family F member 5 (SERPINFB). - HMPL-760 planned dose 1
Phase 1 pipeline
- Fluconazole 400 mg
- Fruquintinib in Combination with Sintilimab
- HMPL-415S1
- HMPL-506
- HMPL-A251
- HMPL-A580
- Surufatinib in combination with Gemcitabine
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about HUTCHMED (China)
What is the ticker symbol for HUTCHMED (China)?
HUTCHMED (China) trades as HCM on the NASDAQ.
What is HUTCHMED (China)'s pipeline?
HUTCHMED (China) has 2 drugs in Phase 3, 2 in Phase 2, 7 in Phase 1. Late-stage candidates include HMPL-760, R-GemOx.
How many employees does HUTCHMED (China) have?
HUTCHMED (China) has approximately 1,796 employees.
Related
- Sector hub: All tracked pharma companies
- Ticker: HCM · NASDAQ